Abstract
The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.
Original language | English |
---|---|
Pages (from-to) | 606-612 |
Journal | Acta Neurochirurgica |
Volume | 139 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1997 |
Subject classification (UKÄ)
- Radiology and Medical Imaging
Free keywords
- Boron neutron capture therapy
- glioma
- BSH